Estimating the effect of antiretroviral treatment during HIV seroconversion: Impact of confounding in observational data

HIV Medicine

Volumn 4, Issue 4, 2003, Pages 332-337

  Porter, K ^a   Law, Matthew ^b   Dabis, Francois ^c   Thiebaut, Rodolphe ^c   Chêne, Geneviève ^c   Lawson Ayayi, Sylvie ^c   Meyer, Laurence ^c   Boufassa, Faroudy ^c   Hamouda, Osamah ^c   Fischer, Klaus ^c   Pezzotti, Patrizio ^c   Rezza, Giovanni ^c   Touloumi, Giota ^c   Hatzakis, Angelos ^c   Karafoulidou, Anastasia ^c   Katsarou, Olga ^c   Brettle, Ray ^d   Del Amo, Julia ^e   del Romero, Jorge ^e   van Asten, Liselotte ^f   van Benthem, Birgit ^f   Prins, Maria ^f   Coutinho, Roel ^f   Kirk, Ole ^g   Pedersen, Court ^g   Hernández Aguado, Ildefonso ^h   Pérez Hoyos, Santiago ^h   Eskild, Anne ⁱ   Bruun, Johan N ⁱ   Sannes, Mette ⁱ   Sabin, Caroline ^c   Lee, Christine ^c   Johnson, Anne M ^c   Phillips, Andrew N ^c   Babiker, Abdel ^c   Darbyshire, Janet H ^c   Gill, Noël ^c   Porter, Kholoud ^c   Francioli, Patrick ^c   Vanhems, Philippe ^c,m   Egger, Matthias ^c   Rickenbach, Martin ^c   Cooper, David ^j,k   Kaldor, John ^j,k   Ashton, Lesley ^j,k   Vizzard, Jeanette ^k   Muga, Roberto ^l   Day, Nicholas E ⁿ   De Angelis, Daniela ⁿ   more..

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Aquitaine Cohort ^*  (Switzerland)

^d Edinburgh Hospital Cohort   (United Kingdom)

^e Madrid Cohort   (Spain)

^f Homosexual Men/Drug Users   (Netherlands)

^g Greek Haemophilia Cohort ^*  (Denmark)

^h Valencia IDU Cohort   (Spain)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j Sydney AIDS Prospective Study   (Australia)

^k Sydney Primary HIV Infection Cohort   (Australia)

^l Badalona IDU Hospital Cohort   (Spain)

^m Lyon Primary Infection Cohort   (France)

ⁿ MRC BIOSTATISTICS UNIT   (United Kingdom)

more..

Author keywords

Antiretroviral therapy; HIV; Seroconverters

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUSTRALIA; CELL COUNT; CLINICAL OBSERVATION; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DISEASE COURSE; DRUG USE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; ANTI-RETROVIRAL AGENTS; AUSTRALIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); EUROPE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0142155197     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00168.x     Document Type: Article

References (13)

1. Mellors JW, Kingsley LA, Rinaldo CR Jr et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
2. Kinloch-de Loes S, Hirschel BJ, Hoen B et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-413.
3. Lindback S, Vizzard J, Cooper DA, Gaines H. Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179: 1549-1552.
4. Niu MT, Bethel J, Holodniy M, Standiford HC, Schnittman SM. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis 1998; 178: 80-91.
5. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
6. Rosenberg ES, Altfeld M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-526.
7. Smith D, Berrey MM, Robertson M et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182: 950-954.
8. Riva E, Pistello M, Narciso P et al. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17: 1599-1604.
9. Tilling R, Kinloch S, Goh LE et al. Parallel decline of CD8 + / CD38 + + T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 589-596.
10. National Institute of Health. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. Ann Intern Med 1998; 128: 1057-1078.
11. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13: 2075-2082.
12. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1: 224-231.
13. CASCADE Collaboration. The relationships between the HIV test interval, demographic factors and HIV disease progression. Epidemiol Infect 2001; 127: 91-100.